Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Traws Pharma (TRAW) Non-cash Items (2016 - 2025)

Traws Pharma (TRAW) has disclosed Non-cash Items for 13 consecutive years, with $456900.0 as the latest value for Q4 2025.

  • For Q4 2025, Non-cash Items fell 83.07% year-over-year to $456900.0; the TTM value through Dec 2025 reached $456900.0, down 83.07%, while the annual FY2025 figure was $456900.0, 19.63% up from the prior year.
  • Non-cash Items hit $456900.0 in Q4 2025 for Traws Pharma, up from $85000.0 in the prior quarter.
  • Across five years, Non-cash Items topped out at $2.7 million in Q4 2024 and bottomed at $21000.0 in Q4 2023.
  • Average Non-cash Items over 5 years is $672134.4, with a median of $397339.5 recorded in 2023.
  • Year-over-year, Non-cash Items surged 12747.62% in 2024 and then crashed 94.69% in 2025.
  • Traws Pharma's Non-cash Items stood at $24261.0 in 2021, then skyrocketed by 858.28% to $232488.0 in 2022, then plummeted by 90.97% to $21000.0 in 2023, then soared by 12747.62% to $2.7 million in 2024, then tumbled by 83.07% to $456900.0 in 2025.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $456900.0, $85000.0, and $263000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.